Stimwave issued a statement today in response to a complaint made by Nevro in Federal Court Delaware District last week alleging Stimwave is infringing Nevro’s patents covering inventions relating to that company’s neurostimulation technology. Stimwave maintains that the claims in the lawsuit are completely baseless, unfounded and invalid.
“Stimwave has never practiced the methods or art stated in any Nevro patent,” said Laura Tyler Perryman, founder and CEO of Stimwave. “Receivers and signal delivery devices have been utilising kHz frequency ranges for over 40 years. We plan to rigorously respond to this action and proceed with a motion to dismiss in the coming months as well as evaluate separate actions.”
Stimwave offers the only wireless micro-sized device cleared by the US Food and Drug Administration (FDA) on the market, to treat chronic neuropathic pain throughout the body, from back and leg pain addressed by spinal cord stimulation to peripheral nervous system treatment for foot and ankle pain, shoulder pain, wrist and elbow pain, knee pain, hip pain and more, allowing more patients to be treated more than ever before with a viable, affordable alternative to help fight opioid usage across the country.